Division of Hematology
In the Division of Hematology at Children's Hospital of Philadelphia, we provide inpatient and outpatient services for children with hematologic disorders. Our patients are cared for by a multidisciplinary team in a setting designed specifically for children and their families.
FDA Approves Two Gene Therapies for Sickle Cell Disease
The Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel) and LYFGENIA™ (lovotibeglogene autotemcel), the first two gene therapies for the treatment of sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).